Belarus versus Russia, Kazakhstan and Armenia: Registration and Compliance Differences
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Belonging to the Eurasian Economic Union does not mean that registration arrangements are the same. In 2026 Belarus maintained a parallel national procedure that has just completed a changeover of its rules; member states still differ in how the transition period applies, in the degree to which national procedures are retained, and in how their competent authorities are organized. For a manufacturer planning multi-country access, the Union is best understood as a common legal ceiling rather than a uniform operating procedure: the Agreement and the decisions of the Eurasian Economic Commission define the shared framework, but everything operational — deadlines, authorities, document expectations, liaison channels — is decided at member-state level. The differences are large enough that a market-access plan built on one member state and extended by analogy to the others will produce wrong schedules, wrong counterparties and wrong cost estimates in most cases.
2. Legal basis
| Instrument | Number / registration | Adoption / entry into force | Provision |
|---|---|---|---|
| Agreement on Unified Principles and Rules for the Circulation of Medical Devices in the EAEU | — | 2014-12-23 | Common Union framework |
| Resolution on the State Registration (Re-registration) of Medical Devices | Council of Ministers No. 211 (6-1/55925) | In force 2026-05-01 | Current rules of the Belarusian national procedure |
| Protocol extending the transition period | — | Signed 2025-12-29 | Transition arrangements applicable jointly to the member states |
| Resolution on Amending Several Resolutions of the Council of Ministers | Council of Ministers No. 378 (6-2/56159) | In force 2026-07-30 | Restructuring of Belarusian regulatory functions |
3. Expert insights
Insight 1: the common framework is the same, but the national procedures differ. The Union Agreement and the decisions of the Eurasian Economic Commission form the common framework, yet whether each member state retains a national procedure, until when, and under what specific rules is decided by the member state itself. The choice made by Belarus is to retain the national procedure and, in 2026, to restructure it for higher efficiency. Other member states make different choices with different timelines. This means the answer to the question of whether a national filing is possible, and how long it takes, must be assembled country by country rather than generalized from a single example.
Insight 2: the Belarusian changeover of 2026 is a predictable source of divergence. Resolution No. 211 compressed the preliminary technical work to 90 calendar days and closed the scope list. Corresponding arrangements do not necessarily exist in other member states. When building multi-country schedules, manufacturers must not apply the Belarusian 90-day baseline to other countries, because doing so silently imports a deadline that no other authority has committed to. Each country’s timeline needs its own source, its own confirmation and its own risk margin in the master plan.
Insight 3: the setup of the competent authorities differs from country to country. Belarus follows a three-segment model: the Ministry of Health takes the decision, an expert body performs the technical work, and a supervisory institution manages the post-market phase. Other member states organize their authorities and their division of functions differently. For multi-country projects, manufacturers should build a separate liaison map for every country — who decides, who reviews, who inspects, and who receives post-market submissions — because the map built for one country will be wrong for the next.
Insight 4: a registration certificate from one country does not automatically cover another. This is the most common misconception in cross-border projects. A certificate obtained in one member state gives lawful access to another member state only through listing that country as a recognizing state within the Union path, or through a separate application under that country’s national procedure. Distributors sometimes assume otherwise, and manufacturers who have not verified the coverage relationship can find themselves supplying a market on an invalid legal basis — a risk that is entirely avoidable with an early, per-country confirmation.
4. Practical recommendations
- Build a liaison map country by country. Do not infer one member state’s authority setup from another; document the deciding, reviewing and supervisory bodies for each target country separately.
- Do not apply deadlines across member states. The Belarusian 90-day baseline applies only to the Belarusian national procedure, and every other country needs its own confirmed timeline.
- Select the path according to the list of target countries. Covering 1 member state and covering several member states lead to different optimal paths, so fix the country list before fixing the path.
- Confirm certificate coverage separately for each country. For every certificate already obtained, verify per country whether a recognition procedure or a separate application is required before supplying that market.
5. Verification checklist
- □ A separate liaison map has been built for each target member state
- □ Deadlines have not been applied across member states
- □ The national or Union path has been selected according to the number of target countries
- □ Certificate coverage relationships have been confirmed country by country
- □ The Union common framework and the national rules of each country are managed separately
Regulatory information verified as of 30 October 2026.
In the Eurasian Economic Union market, GRZAN concentrates its core capabilities on three fronts. First, distinguishing the applicable conditions and the remaining time windows of the two channels — Union-level unified registration and national registration in each member state. The national registration procedure of Belarus has been fully restructured by Council of Ministers Resolution No. 211 of 28 April 2026 (state registration number 6-1/55925, in force 1 May 2026): the total time limit for preliminary technical work is compressed to 90 calendar days, the scope list is closed and implementing organizations are prohibited from expanding it, while the window for filing applications under the national procedure takes 31 December 2027 as the key milestone, so path selection must be decided in step with the time window. Second, local authorized representative services: GRZAN acts as the statutory representative of the manufacturer in Belarus, handling registration filings, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has already synchronized its liaison mechanisms after Council of Ministers Resolution No. 378 of 27 July 2026 (in force 30 July 2026) transferred adverse event functions to the State Institution for State Pharmaceutical Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and organizes technical documentation according to the target path — the national path follows the annex to Ministry of Health Resolution No. 55, while the Union path follows Eurasian Economic Commission Council Decision No. 46. For post-market compliance in the Belarusian market — vigilance, recalls and responses to supervisory inspections — GRZAN provides end-to-end support built on the same framework.
Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us